>
Switch to:

ORIC Pharmaceuticals ROC (Joel Greenblatt) %

: -4,436.56% (As of Jun. 2021)
View and export this data going back to 2020. Start your Free Trial

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. ORIC Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was -4,436.56%.

The historical rank and industry rank for ORIC Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

NAS:ORIC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3453.78   Med: -1201.64   Max: -889.86
Current: -3453.78

-3453.78
-889.86

During the past 3 years, ORIC Pharmaceuticals's highest ROC (Joel Greenblatt) % was -889.86%. The lowest was -3453.78%. And the median was -1201.64%.

NAS:ORIC's ROC (Joel Greenblatt) % is ranked lower than
99.99% of the 318 Companies
in the Biotechnology industry.

( Industry Median: -691.89 vs. NAS:ORIC: -3453.78 )

ORIC Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


ORIC Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

The historical data trend for ORIC Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20
ROC (Joel Greenblatt) %
-889.86 -1,201.64 -2,337.42

ORIC Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
ROC (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,184.19 -2,610.38 -3,388.75 -3,352.51 -4,436.56

Competitive Comparison

For the Biotechnology subindustry, ORIC Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

ORIC Pharmaceuticals ROC (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where ORIC Pharmaceuticals's ROC (Joel Greenblatt) % falls into.



ORIC Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.96) - (4.135 + 0 + 1.686)
=-3.861

Working Capital(Q: Jun. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.884) - (5.892 + 0 + 2.398)
=-4.406

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of ORIC Pharmaceuticals for the quarter that ended in Jun. 2021 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2021  Q: Jun. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-84.228/( ( (1.969 + max(-3.861, 0)) + (1.828 + max(-4.406, 0)) )/ 2 )
=-84.228/( ( 1.969 + 1.828 )/ 2 )
=-84.228/1.8985
=-4,436.56 %

Note: The EBIT data used here is four times the quarterly (Jun. 2021) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ORIC Pharmaceuticals  (NAS:ORIC) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


ORIC Pharmaceuticals ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of ORIC Pharmaceuticals's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


ORIC Pharmaceuticals Business Description

ORIC Pharmaceuticals logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533.
Executives
Kunkel Lori Anne director C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085
Chacko Jacob director, officer: President and CEO C/O IGNYTA, INC. 11095 FLINTKOTE AVE., SUITE D SAN DIEGO CA 92121
Topspin Biotech Fund Ii, L.p. 10 percent owner 3 EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Lg Management, Llc 10 percent owner THREE EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Topspin Fund L.p. 10 percent owner THREE EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Heyman Richard A. director 5871 OBERLIN DRIVE, SUITE 150 SAN DIEGO CA 92121
Scheller Richard H director C/O GENENTECH INC 1 DNA WAY MS 49 SOUTH SAN FRANCISCO CA 94080-4990
Guthart Leo 10 percent owner C/O APTUR GROUP INC 475 W TERRA COTTA AVE STE E CRYSTAL LAKE IL 60014
Column Group Ii Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158
Goeddel David V 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Svennilson Peter director, 10 percent owner 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Gordon Carl L director, 10 percent owner 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Orbimed Capital Gp Vi Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022

ORIC Pharmaceuticals Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)